A Phase I trial for JCAR023, a CAR product candidate directed against cancers expressing L1CAM in patients with recurrent or refractory pediatric neuroblastoma

Trial Profile

A Phase I trial for JCAR023, a CAR product candidate directed against cancers expressing L1CAM in patients with recurrent or refractory pediatric neuroblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs JCAR 023 (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2015 New trial record
    • 18 Mar 2015 According to a Juno Therapeutics media release, first patient has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top